분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-10-23 14:31:28 , Hit : 1367
 Novartis Extends Deal to Use SomaLogic Proteomics Technology


GEN News Highlights
Oct 20, 2014

Three years into a multi-year research agreement to use SomaLogic’s proteomics technology in its drug-development efforts, Novartis has extended the deal and will take an equity position in the privately held life-sci tools and clinical diagnostics developer.

Neither the value of the extended deal nor the length of the extension has been disclosed.

In a statement today, SomaLogic did say the companies agreed to “enhance and expand” efforts undertaken as part of the collaboration. Under their previous agreement, researchers at the Novartis Institutes for BioMedical Research (NIBR) and SomaLogic joined to build an enhanced version of SomaLogic's SOMAscan™ proteomics assay for NIBR, as well as develop specific SOMAmer® (Slow Off-rate Modified Aptamer) protein-binding reagents for multiple preclinical and clinical applications in NIBR’s research and development portfolio.

“Our ongoing relationship with Novartis is a model for how we seek to develop strong scientific collaborations that drive new discoveries and build value for both parties,” SomaLogic CEO Byron Hewett said in a statement.

SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of protein-binding reagents designed to combine the best properties of both monoclonal antibodies and traditional aptamers. They can be applied in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods.

No fewer than 1,129 different SOMAmer reagents are incorporated into SomaLogic’s commercially available SOMAscan assay, which is designed to efficiently, accurately, and rapidly measure proteins across a range of concentrations in just a few drops of blood or other tissues through binding to individual proteins and nucleic acid-based quantification.

SomaLogic offerings are intended to aid researchers in protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.  







807   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1743
806   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1673
805   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1601
804   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1351
803   실험실에서 만든 인공위장  이성욱 2014/11/04 1309
802   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1562
801   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1672
800   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1659
799   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1413
798   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2871
797   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1548
796   피부암 외에도 다른 위험성이 있는 햇빛  이성욱 2014/10/24 1563
  Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1367
794   여성은 남성보다 현명한 의사결정자일까?  이성욱 2014/10/23 1530
793   스위칭 오프할 수 있는 리보자임(ribozyme)의 개발과 유전자치료 (우리실험실 결과소개)  이성욱 2014/10/17 2407
792   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1774
791   CAR T 세포를 이용한 효과적인 항암 치료법  이성욱 2014/10/15 2139
790   Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval  이성욱 2014/10/14 1926
789   20년간 숨어 있던 폐암의 비밀  이성욱 2014/10/14 1553
788   특정 염색체 구조가 중요 유전자 조절  이성욱 2014/10/14 1947

[이전 10개] [1]..[21][22][23] 24 [25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN